Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Theresa Proia"'
Autor:
Jamal Carlos Saeh, Justin Cidado, Lisa Drew, Stephen Fawell, Michelle Min Wu, Neeraj Kumar Aryal, Gareth P. Gregory, Maureen Hattersley, Wenlin Shao, Theresa Proia, Maryann San Martin, Ricky W. Johnstone, Scott Boiko
Publikováno v:
Blood
BH3 mimetics like venetoclax target prosurvival Bcl-2 family proteins and are important therapeutics in the treatment of hematological malignancies. We demonstrate that endogenous Bfl-1 expression can render preclinical lymphoma tumor models insensit
Autor:
Tieguang Yao, Liangwei Wu, Craig S. Donald, Douglas Ferguson, Lei Wang, Andrew Pike, Jianyan Wang, Justin Cidado, Dedong Wu, Kurt Gordon Pike, Kumar Thakur, Chungang Gu, Calum Cook, James Horstick, Tyler Grebe, Theresa Proia, Darren Stead, Alexander Hird, Michelle Lamb, Wenlin Shao, Nichole O'Connell, Yun Jiang, Sudhir M. Hande, Bin Yang, Janet Hawkins, Barlaam Bernard Christophe, Neil Sumner, Melissa Vasbinder, Andrew D. Ferguson, Jane E. Moore, Jeffrey G. Varnes, Bryan Roberts, Maryann San Martin, Lisa Drew, Ujjal Sarkar, Allan Dishington, Chris De Savi, Robert Casella, Steve C. Glossop, Jane L. Holmes, Thomas M. McGuire
Publikováno v:
Journal of Medicinal Chemistry. 63:15564-15590
A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2), focusing o
Autor:
A. Hughes, Patricia McCoon, Stephen Fawell, Gayathri Bommakanti, Simon T. Barry, Deanna A. Mele, Larissa S. Carnevalli, Christopher Womack, Michael Collins, Nanhua Deng, Lukasz Magiera, Mingchao Xie, J. Carl Barrett, Richard Woessner, Srimathi S. Srinivasan, Deanna L. Russell, Shaun E Grosskurth, Corinne Reimer, Maneesh Singh, Minwei Ye, Theresa Proia, Matthew Griffin, Susan Cantin
Publikováno v:
Clinical Cancer Research. 26:6335-6349
Purpose: Danvatirsen is a therapeutic antisense oligonucleotide (ASO) that selectively targets STAT3 and has shown clinical activity in two phase I clinical studies. We interrogated the clinical mechanism of action using danvatirsen-treated patient s
Autor:
Dallin Milner, Jason S. Williams, Karyn A. Goodman, Michael J. Gough, Thomas E. Bickett, Wells A. Messersmith, Benjamin Van Court, Eric T. Clambey, Theresa Proia, Kimberly R. Jordan, Sana D. Karam, Richard D. Schulick, Ayman Oweida, Shilpa Bhatia, Andy Phan, Kirk C. Hansen, Miles Piper, Adam C. Mueller, Marco Del Chiaro
Publikováno v:
Cancer Immunology, Immunotherapy. 70:989-1000
Pancreatic ductal adenocarcinoma (PDAC) has a heterogeneous tumor microenvironment (TME) comprised of myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages, neutrophils, regulatory T cells, and myofibroblasts. The precise mechanisms
Autor:
Yanjun Wang, Sigourney Bell, A. Hughes, Theresa Proia, Neha Wali, Pablo Morentin Gutierrez, Matthew A. King, Larissa S. Carnevalli, Molly A. Taylor, Danielle Carroll, Michele Moschetta, Maneesh Singh, Antonio Ramos-Montoya, Cristina Gardelli, Stephen Fawell, Simon T. Barry, Anna M. L. Coenen-Stass, Teresa Klinowska, Susan E. Critchlow
Publikováno v:
Molecular cancer therapeutics. 20(6)
Suppressive myeloid cells mediate resistance to immune checkpoint blockade. PI3Kγ inhibition can target suppressive macrophages, and enhance efficacy of immune checkpoint inhibitors. However, how PI3Kγ inhibitors function in different tumor microen
Autor:
Emma Minihane, Jonathan R. Dry, Simon J. Cook, Mario Aladren Vicente, Matthew J. Sale, Noel R. Monks, Paul D Smith, Aleksandra Markovets, Lisa Drew, Duncan I. Jodrell, Frances M. Richards, Theresa Proia, Courtney L. Andersen, Emma J. Davies, Vikki Flemington, Eiko Ozono, Rebecca Gilley, Kevin Schifferli
Publikováno v:
Nature Communications
Nature Communications, Vol 10, Iss 1, Pp 1-19 (2019)
Nature Communications, Vol 10, Iss 1, Pp 1-19 (2019)
BRAF and MEK1/2 inhibitors are effective in melanoma but resistance inevitably develops. Despite increasing the abundance of pro-apoptotic BIM and BMF, ERK1/2 pathway inhibition is predominantly cytostatic, reflecting residual pro-survival BCL2 famil
Autor:
Chandra Sekhar Reddy Chilamakuri, Clive D'Santos, Stephen Fawell, Michael Zinda, David M. Weinstock, Nancy Su, Valar Nila Roamio Franklin, Petar Pop-Damkov, Jamal Carlos Saeh, Raphael Koch, Wenlin Shao, Steven Criscione, Justin Cidado, Scott Boiko, Lisa Drew, Maryann San Martin, Theresa Proia, Douglas Ferguson
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(4)
Purpose: Cyclin-dependent kinase 9 (CDK9) is a transcriptional regulator and potential therapeutic target for many cancers. Multiple nonselective CDK9 inhibitors have progressed clinically but were limited by a narrow therapeutic window. This work de
Autor:
Theresa Proia, Anna Staniszewska, Mark J. O'Connor, Joshua Armenia, Chrysiis Michaloglou, Matthew A. King, Maryann San Martin, Zena Wilson, Elisabetta Leo, Oona Delpuech, Viia Valge-Archer, Maneesh Singh
Publikováno v:
Cancer Research. 80:967-967
PARP inhibitor treatments are synthetically lethal with BRCA1/2 mutations and, in this setting, accumulation of DNA damage leads ultimately to cell death. Increases in DNA damage are also associated with increased levels of cytosolic DNA and conseque
Autor:
Horma Ghadially, Kristina M. Ilieva, Scott Mlynarski, Alwin Schuller, Theresa Proia, Wenlin Shao, Eric Gangl, Sharon Tentarelli, Aatman Doshi, Susan Cantin, Michael Secinaro, Yanjun Wang, Laura Prickett, Ray Finlay
Publikováno v:
Cancer Research. 80:4523-4523
The tumor microenvironment (TME) has multiple mechanisms of immune-suppression, one being recruitment of arginase (ARG) expressing myeloid cells. ARG is an enzyme that catalyzes hydrolysis of L-arginine into urea and L-ornithine. L-arginine is a semi
Abstract 2500: Transient CDK9 inhibition with AZD4573 modulates Bfl-1 in preclinical lymphoma models
Publikováno v:
Cancer Research. 79:2500-2500
AZD4573 is a selective cyclin-dependent kinase 9 (CDK9) inhibitor under clinical development in patients with hematological malignancies. Transient CDK9 inhibition serves as an orthogonal approach for targeting Mcl-1, a labile anti-apoptotic protein